Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FluBHPVE6E7 in HPV16+ Oropharyngeal Squamous Cell Carcinoma
NCT06589609Phase 1Recruiting
- Sponsor
- BlueSky Immunotherapies
- Start
- Aug 2024
- Primary completion
- Nov 2027
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of FluBHPVE6E7 in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by BlueSky Immunotherapies. Primary endpoint: Frequency and severity of adverse events (AEs) at 7 days. Started Aug 2024; status: recruiting.
02
Drugs
FluBHPVE6E7
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT06589609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06589609.